Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gut

• Publication date

  2014-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gutjnl-2014-307126PMID 24970900
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UvA-DARE ( Digital Academic Repository ) Crohn ’ s disease : Mucosal immunology and immune modulating therapy

  2014cited by this paper
• Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients.

  2014cited by this paper
• Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry

  2014cited by this paper
• Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.

  2014cited by this paper
• Predictors of response to Infliximab in children with luminal Crohn's disease.

  2014cited by this paper
• Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.

  2014cited by this paper
• Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease.

  2014cited by this paper
• Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center

  2014cited by this paper
• Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis–Predominant IBD

  2014cited by this paper
• Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

  2014cited by this paper
• Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

  2014cited by this paper
• Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohn's Disease

  2014cited by this paper
• Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐α therapy in inflammatory bowel disease

  2014cited by this paper
• Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

  2014cited by this paper
• Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis

  2014cited by this paper
• Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

  2014cited by this paper
• A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease

  2014cited by this paper
• Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

  2014cited by this paper
• Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment

  2014cited by this paper
• Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.

  2014cited by this paper
• Time of infliximab therapy initiation and dose escalation in Crohn's disease.

  2014cited by this paper
• Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

  2014cited by this paper
• Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

  2014cited by this paper
• Do Inflammatory Bowel Disease Therapies Cause Cancer?

  2013cited by this paper
• Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

  2013cited by this paper
• Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease

  2013cited by this paper
• High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.

  2013cited by this paper
• Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

  2013cited by this paper
• Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

  2013cited by this paper
• Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

  2013cited by this paper
• Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease

  2013cited by this paper
• SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.

  2013cited by this paper
• Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

  2013cited by this paper
• Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.

  2013cited by this paper
• Clinical Outcomes and Management of Inflammatory Bowel Disease in the Older Patient

  2013cited by this paper
• Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.

  2013cited by this paper
• When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.

  2013cited by this paper
• Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

  2013cited by this paper
• Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study

  2013cited by this paper
• Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

  2013cited by this paper
• Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

  2013cited by this paper
• Ten Years of Infliximab for Crohn’s Disease: Outcome in 469 Patients from 2 Tertiary Referral Centers

  2013cited by this paper
• Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.

  2013cited by this paper
• Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

  2013cited by this paper
• Biologics: Targets and Therapy

  2013cited by this paper
• 979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data

  2013cited by this paper
• Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease

  2013cited by this paper
• Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.

  2013cited by this paper
• One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

  2013cited by this paper
• Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.

  2013cited by this paper
• Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

  2013cited by this paper
• Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

  2013cited by this paper
• Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.

  2013cited by this paper
• T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study

  2013cited by this paper
• Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review

  2013cited by this paper
• Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission

  2013cited by this paper
• Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.

  2013cited by this paper
• Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease

  2013cited by this paper
• The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

  2013cited by this paper
• Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

  2012cited by this paper
• Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission.

  2012cited by this paper
• The decline of anti‐drug antibody titres after discontinuation of anti‐TNFs: implications for predicting re‐induction outcome in IBD

  2012cited by this paper
• Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

  2012cited by this paper
• Durability of Infliximab Dose Intensification in Crohn’s Disease

  2012cited by this paper
• Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

  2012cited by this paper
• Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

  2012cited by this paper
• A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease

  2012cited by this paper
• Adalimumab in active ulcerative colitis: a "real-life" observational study.

  2012cited by this paper
• Long‐term durability of response to adalimumab in Crohn's disease

  2012cited by this paper
• Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

  2012cited by this paper
• Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease.

  2012cited by this paper
• Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

  2012cited by this paper
• Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

  2012cited by this paper
• Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study

  2012cited by this paper
• Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

  2012cited by this paper
• Does co‐treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

  2012cited by this paper
• Long‐term outcome of a third anti‐TNF monoclonal antibody after the failure of two prior anti‐TNFs in inflammatory bowel disease

  2012cited by this paper
• Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

  2012cited by this paper
• Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

  2012cited by this paper
• Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.

  2011cited by this paper
• Certolizumab pegol for the treatment of Crohn’s disease

  2011cited by this paper
• Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study

  2011cited by this paper
• Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

  2011cited by this paper
• Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications.

  2011cited by this paper
• A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

  2011cited by this paper
• Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

  2011cited by this paper
• The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

  2011cited by this paper
• Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

  2011cited by this paper
• Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease

  2011cited by this paper
• Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

  2011cited by this paper
• Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

  2011cited by this paper
• Long‐term outcome of treatment with infliximab in pediatric‐onset Crohn's disease: A population‐based study

  2011cited by this paper
• Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort

  2010cited by this paper
• Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

  2010cited by this paper
• Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients

  2010cited by this paper
• Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

  2010cited by this paper
• A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization

  2010cited by this paper
• The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies

  2010cited by this paper

• Natural Nanoparticles for Drug Delivery: Proteomic Insights and Anticancer Potential of Doxorubicin-Loaded Avocado Exosomes

  2025cites this paper
• Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease

  2025cites this paper
• Understanding the therapeutic toolkit for inflammatory bowel disease

  2025cites this paper
• Gut–Brain–Microbiota Axis in Irritable Bowel Syndrome: A Narrative Review of Pathophysiology and Current Approaches

  2025cites this paper
• Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial

  2025cites this paper
• Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis

  2024cites this paper
• Real-World Experience of the Association of HLADQA1*05 Allele With Loss of Response to Anti-TNF Inhibitors

  2024cites this paper
• Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach

  2024cites this paper
• Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus

  2024cites this paper
• Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.

  2023cites this paper
• Squamous cell carcinoma and Crohn's disease: a sometimes-challenging diagnosis

  2023cites this paper
• Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.

  2023cites this paper
• A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy

  2023cites this paper
• Multi-omics analysis reveals the interaction of gut microbiome and host microRNAs in ulcerative colitis

  2023cites this paper
• HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.

  2023cites this paper
• Combination therapy in inflammatory bowel disease: Current evidence and perspectives.

  2023cites this paper
• Plant-Derived Exosomes as a Drug-Delivery Approach for the Treatment of Inflammatory Bowel Disease and Colitis-Associated Cancer

  2022cites this paper
• Medical Treatment Options for Ulcerative Colitis

  2022cites this paper
• Zingiber officinale (Ginger) as a treatment for inflammatory bowel disease: A review of current literature

  2022cites this paper
• The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

  2022cites this paper
• Ambroxol, a mucolytic agent, boosts HO‐1, suppresses NF‐κB, and decreases the susceptibility of the inflamed rat colon to apoptosis: A new treatment option for treating ulcerative colitis

  2022cites this paper
• Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: A clinicopathological study of 15 cases.

  2022cites this paper
• Multi-omics analyses of the Ulcerative Colitis gut microbiome link Bacteroides vulgatus proteases with disease severity

  2021cites this paper
• Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis

  2021cites this paper
• Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis

  2021cites this paper
• Medical and Endoscopic Management of Crohn Disease.

  2021cites this paper
• Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease.

  2021cites this paper
• Anti‐TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta‐analysis

  2021cites this paper
• Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

  2021cites this paper
• Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.

  2021cites this paper
• Polyphenols from food by-products: An alternative or complementary therapy to IBD conventional treatments.

  2021cites this paper
• A pH/ultrasonic dual-response step-targeting enterosoluble granule for combined sonodynamic-chemotherapy guided via gastrointestinal tract imaging in orthotopic colorectal cancer.

  2021cites this paper
• Rate of Reoperation Decreased Significantly After Year 2002 in Patients with Crohn's Disease.

  2020cites this paper
• The Proteolytic Fraction From Vasconcellea cundinamarcensis Latex Displays Anti-Inflammatory Effect in A Mouse Model of Acute TNBS-Induced Colitis

  2020cites this paper
• Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

  2020cites this paper
• Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients

  2020cites this paper
• Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

  2020cites this paper
• Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease.

  2020cites this paper
• Graphene quantum dots as anti-inflammatory therapy for colitis

  2020cites this paper
• Histology at diagnostic gastroscopy predicts outcome after intestinal resection in pediatric Crohn's disease

  2020cites this paper
• Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases.

  2020cites this paper
• Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn's Disease.

  2020cites this paper
• Lymphoma Risk and Screening in IBD

  2019cites this paper
• Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles

  2019cites this paper
• Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win.

  2019cites this paper
• Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance

  2019cites this paper
• An advanced protocol for the purification of whipworm eggs from feces for use as therapeutic agents.

  2019cites this paper
• Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease

  2019cites this paper
• US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.

  2019cites this paper
• Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?

  2019cites this paper
• Earlier discontinuation of TNF‐α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects

  2019cites this paper
• Medical management of Crohn’s disease: state of the art and future perspectives

  2019cites this paper
• VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.

  2019cites this paper
• Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

  2019cites this paper
• Response to Gupta and Hanauer.

  2019cites this paper
• Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

  2018cites this paper
• Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease

  2018cites this paper
• The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study.

  2018cites this paper
• Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease

  2018cites this paper
• Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

  2018cites this paper
• Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate‐severe flares: a phase 2A pilot multi‐center, randomized, double‐blind, sham‐controlled trial

  2018cites this paper
• Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants

  2018cites this paper
• Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival.

  2018cites this paper
• Low Doses of Azathioprine are Effective in Combination With Infliximab in Inflammatory Bowel Disease but May not be During Induction Therapy.

  2018cites this paper
• Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.

  2018cites this paper
• Biologics and immunomodulators for treating Crohn’s disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature

  2018cites this paper
• Investigating the natural history, serologic and genetic associations with disease outcomes, disability and cost of care in inflammatory bowel disease

  2018cites this paper
• Acute severe ulcerative colitis: latest evidence and therapeutic implications

  2018cites this paper
• The Use of Concomitant Immunomodulators with Adalimumab Therapy in Pediatric Crohn’s Disease

  2018influential citation
• Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

  2018cites this paper
• Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know

  2017cites this paper
• The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis

  2017cites this paper
• Combination Therapy for Inflammatory Bowel Disease.

  2017cites this paper
• Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease

  2017cites this paper
• Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

  2017cites this paper
• Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

  2017cites this paper
• Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial

  2017cites this paper
• Crohn Disease: Epidemiology, Diagnosis, and Management

  2017cites this paper
• Crohn's disease

  2017cites this paper
• The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease

  2017cites this paper
• Fourteen-Year Anti-TNF Therapy in Crohn’s Disease Patients: Clinical Characteristics and Predictive Factors

  2017cites this paper
• Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

  2017cites this paper
• The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

  2017cites this paper
• ADVANCES IN IBD

  2017cites this paper
• Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

  2017cites this paper
• Benzimidazoles Promote Anti-TNF Mediated Induction of Regulatory Macrophages and Enhance Therapeutic Efficacy in a Murine Model

  2017cites this paper
• Golimumab for the treatment of ulcerative colitis

  2017cites this paper
• Methotrexate for Inflammatory Bowel Diseases - New Developments

  2016cites this paper
• Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

  2016cites this paper
• Thiopurine Metabolism in the Era of Combotherapy

  2016cites this paper
• How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

  2016cites this paper
• Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

  2016cites this paper
• The Future of IBD Therapy: Where Are We and Where Should We Go Next?

  2016cites this paper
• Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.

  2016cites this paper
• The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

  2016cites this paper
• A microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow.

  2016cites this paper
• Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.

  2016cites this paper
• Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

  2016cites this paper
• Treatment of Inflammatory Bowel Disease and Colitis-Associated Cancer

  2016cites this paper
• Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives

  2016cites this paper